Claims for Patent: 8,697,071

Summary for Patent: 8,697,071

Title:	Identification and engineering of antibodies with variant Fc regions and methods of using same
Abstract:	The present invention relates to molecules comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc.gamma.RIIIA and/or Fc.gamma.RIIA with a greater affinity relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are useful in preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by Fc.gamma.R is desired, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
Inventor(s):	Stavenhagen; Jeffrey (Brookville, MD), Gorlatov; Sergey (Gaithersburg, MD), Rankin; Christopher (Clarksburg, MD), Tuaillon; Nadine (Gaithersburg, MD)
Assignee:	MacroGenics, Inc. (Rockville, MD)
Application Number:	13/524,652
Patent Claims:	1. A method of increasing antibody-dependent cell mediated cytotoxicity (ADCC) activity by administering to a subject a therapeutically effective amount of an antibody, or an antigen-binding fragment thereof, wherein said antibody or said antigen-binding fragment thereof comprises a variant Fc region including amino acid modifications relative to a wild-type Fc region such that said variant Fc region binds Fc.gamma.RIIIA with a greater affinity relative to an antibody comprising the wild-type Fc region, and wherein said included amino acid modifications comprise: (A) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, a substitution at position 305 with isoleucine, and a substitution at position 396 with leucine; (B) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, and a substitution at position 396 with leucine; or (C) a substitution at position 243 with leucine, a substitution at position 292 with proline, and a substitution at position 300 with leucine; wherein the positions are numbered according to the EU index as in Kabat. 2. The method of claim 1, wherein said variant Fc region further specifically binds Fc.gamma.RIIB with a lower affinity than a comparable antibody comprising the wild-type Fc region binds Fc.gamma.RIIIA or Fc.gamma.RIIB, and wherein said included amino acid modifications are said substitution at position 243 with leucine, said substitution at position 292 with proline, and said substitution at position 300 with leucine. 3. The method of claim 1, wherein said variant Fc region is a human IgG Fc region. 4. The method of claim 3, wherein said human IgG Fc region is a human IgG1, IgG2, IgG3, or IgG4 Fc region. 5. The method of claim 1, wherein said antibody is a monoclonal antibody, a humanized antibody, or a human antibody. 6. The method of claim 1, wherein said antibody is a humanized antibody. 7. The method of claim 1, wherein said antibody comprises a variable domain which binds to CD16A or CD32B. 8. The method of claim 1, wherein said antibody is antibody produced by the cell line 2B6 having a deposit number of ATCC PTA-4591. 9. The method of claim 1, wherein said antibody is a humanized antibody 2B6 (ATCC PTA-4591), and wherein said humanized antibody includes the six CDRs of antibody 2B6. 10. The method of claim 1, wherein said variant Fc region competitively inhibits the binding of antibody 2B6 (ATCC PTA-4591) to CD32B. 11. The method of claim 1, wherein said antibody is trastuzumab, rituximab, an anti-CD14 antibody, edrecolomab, an anti-EGFR IgG antibody, an anti-.alpha.V.beta.3 integrin antibody, an anti CD52 IgG1 antibody, an anti-CD22 antibody, or an anti-CD20 antibody. 12. The method of claim 1, wherein said subject has a cancer characterized by a cancer antigen, and wherein said cancer antigen is a KS 1/4 pan-carcinoma antigen, a melanoma associated or melanoma specific antigen, an ovarian carcinoma antigen (CA125), a prostate specific antigen, a prostate specific membrane antigen, a colorectal tumor-associated antigen, a tumor-specific transplantation type of cell-surface antigen (TSTA), a differentiation antigen, an epidermal growth factor receptor (EFGR) antigen, a HER2/neu antigen, a polymorphic epithelial mucin (PEM) antigen, a malignant human lymphocyte (APO-1) antigen, or a cutaneous T cell lymphoma antigen. 13. The method of claim 1 further comprising the administration of one or more additional cancer therapies. 14. The method of claim 13, wherein said additional cancer therapy is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy, hormonal therapy, or surgery. 15. The method of claim 1, wherein said subject is human. 16. A method for delivering a therapeutic agent to a cancer cell characterized by a cancer antigen and thereby increasing antibody-dependent cell mediated cytotoxicity (ADCC) activity, said method comprising administering to said subject a therapeutically effective amount of an antibody, or an antigen-binding fragment thereof, that binds said cancer antigen, wherein said antibody or said antigen-binding fragment thereof comprises a variant Fc region including amino acid modifications relative to a wild-type Fc region such that said variant Fc region binds Fc.gamma.RIIIA with a greater affinity relative to an antibody comprising the wild-type Fc region, and wherein said included amino acid modifications comprise: (A) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, a substitution at position 305 with isoleucine, and a substitution at position 396 with leucine; (B) a substitution at position 243 with leucine, a substitution at position 292 with proline, a substitution at position 300 with leucine, and a substitution at position 396 with leucine; or (C) a substitution at position 243 with leucine, a substitution at position 292 with proline, and a substitution at position 300 with leucine; wherein the positions are numbered according to the EU index as in Kabat. 17. The method of claim 16, wherein said cancer antigen is a KS 1/4 pan-carcinoma antigen, a melanoma associated or melanoma specific antigen, an ovarian carcinoma antigen (CA125), a prostate specific antigen, a prostate specific membrane antigen, a colorectal tumor-associated antigen, a tumor-specific transplantation type of cell-surface antigen (TSTA), a differentiation antigen, an epidermal growth factor receptor (EFGR) antigen, a HER2/neu antigen, a polymorphic epithelial mucin (PEM) antigen, a malignant human lymphocyte (APO-1) antigen, or a cutaneous T cell lymphoma antigen. 18. The method of claim 16, wherein said cancer cell is a cell from a breast cancer, an ovarian cancer, a prostate cancer, a cervical cancer, or a pancreatic carcinoma cancer.

Details for Patent 8,697,071

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-08-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-08-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-08-10